What is the MoonStone Study?
A Clinical Trial for Multiple Sclerosis (MS)
Are you or a loved one living with multiple sclerosis (MS) in Arizona? An exciting new clinical trial, the MoonStone Study, is now enrolling participants at Arizona Neuroscience Research (www.azneuroscienceresearch.com).
This study is exploring the potential of an investigational drug called obexelimab to safely and effectively treat adults with relapsing forms of MS. If you’re between 18 and 60 years old and have been diagnosed with MS, you may be eligible to participate.
The MoonStone Study is a Phase 2 clinical trial designed to evaluate the safety and efficacy of obexelimab, a new investigational drug for MS. Unlike some existing treatments that deplete B-cells (a type of immune cell involved in MS), obexelimab works by modulating B-cell activity without completely eliminating them. This unique approach could offer a new way to manage MS symptoms and progression.
The study is open to adults with relapsing-remitting MS (RRMS) or active secondary progressive MS (SPMS). Participants will receive either obexelimab or a placebo during the first 12 weeks, followed by an open-label period where everyone receives obexelimab.
Who Can Participate?
To join the MoonStone Study, you must:
- Be between 18 and 60 years old.
- Have a diagnosis of relapsing MS (RRMS or active SPMS).
- Meet additional eligibility criteria, which the study team will discuss with you.
If you’ve experienced at least one relapse in the past year, two relapses in the past two years, or have active lesions on an MRI scan, you may qualify.
What Happens During the Study?
Your participation will last approximately 10 months (40 weeks), including screening, treatment, and follow-up visits. Here’s what to expect:
- Screening Visit
- At least 1 clinic visit for health checks and tests to determine eligibility.
- If you qualify, treatment will begin within 4 weeks.
- Study Treatment Period (Part A)
- Weekly clinic visits for 12 weeks.
- You’ll be randomly assigned to receive either obexelimab (67% chance) or a placebo (33% chance).
- Study Treatment Period (Part B)
- Weekly clinic visits for another 12 weeks.
- All participants will receive obexelimab (no placebo).
- Follow-Up Period
- 1 final clinic visit 12 weeks after your last treatment visit.
What Tests and Health Checks Are Involved?
Throughout the study, you’ll undergo various tests and procedures to monitor your health and the effects of the study drug. These may include:
- Health and medication reviews
- Questionnaires
- Physical and neurological exams
- MRI scans
- Blood and urine tests
- ECG heart tests
- Optional lumbar puncture
Why Participate in the MoonStone Study?
By joining this study, you’ll have the opportunity to:
- Access a cutting-edge investigational treatment for MS.
- Contribute to advancing MS research and helping others living with the condition.
- Receive close medical monitoring and care from experienced healthcare professionals.
Where is the Study Taking Place in Arizona?
The MoonStone Study is being conducted at two locations in Arizona:
- Phoenix, AZ – Center for Neurology and Spine
- Scottsdale, AZ – Perseverance Research Center
How to Learn More or Enroll
If you’re interested in participating or want more information, visit the study website at www.azneuroscienceresearch.com or contact the study team directly:
- Phone: (480) 210-8723
- Email: anr@centerforneurologyandspine.com
Be Part of the Future of MS Treatment
The MoonStone Study represents a promising step forward in the fight against MS. If you’re living with MS in Arizona, this could be your chance to make a difference—for yourself and for others. Don’t miss this opportunity to explore a potential new treatment option.
- MoonStone Study Arizona
- MS clinical trial Phoenix
- MS research Scottsdale
- Obexelimab clinical trial
- Multiple sclerosis study AZ
- Relapsing MS treatment
- Arizona Neuroscience Research
- MS clinical trial near me
- Participate in MS research
- New MS treatment Arizona
Join the MoonStone Study today and take an active role in shaping the future of MS care!
https://www.clinicaltrials.gov/study/NCT06564311#study-overview
https://themoonstonestudy.com/